References
- AstonJLLodolceAEShapiroNLInteraction between warfarin and cranberry juicePharmacotherapy2006261314131916945054
- PhamDQPhamAQInteraction potential between cranberry juice and warfarinAm J Health Syst Pharm20076449049417322161
- MergenhagenKAShermanOElevated International Normalized Ratio after concurrent ingestion of cranberry sauce and warfarinAm J Health Syst Pharm2008652113211618997138
- NutescuEAShapiroNLIbrahimSWestPWarfarin and its interactions with foods, herbs and other dietary supplementsExpert Opin Drug Saf2006543345116610971
- LiljaJJBackmanJTNeuvonenPJEffects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine, and midazolam – probes of CYP2C9, CYP1A2, and CYP3A4Clin Pharmacol Ther20078183383917392729
- Mohammed AbdulMIJiangXWilliamsKMPharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjectsBr J Pharmacol20081541691170018516070
- AnsellJMcDonoughMZhaoYHarmatzJSGreenblattDJThe absence of an interaction between warfarin and cranberry juice: A randomized, double-blind trialJ Clin Pharmacol20094982483019553405
- LiZSeeramNPCarpenterCLThamesGMinuttiCBowermanSCranberry does not affect prothrombin time in male subjects on warfarinJ Am Diet Assoc20061062057206117126638
- PaineMFOberliesNHClinical relevance of the small intestine as an organ of drug elimination: Drug-fruit juice interactionsExpert Opin Drug Metab Toxicol20073678017269895
- NgoNYanZGrafTNIdentification of a cranberry juice product that inhibits enteric CYP3A-mediated first-pass metabolism in humansDrug Metab Dispos20093751452219114462
- BrantleySJOberliesNHKrollDJPaineMFTwo flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrationsJ Pharmacol Exp Ther20103321081108719934397
- Food and Drug Administration, US Department of Health and Human ServicesGuidance for industry: Bioanalytical method validationRockville, MD2001 Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdfAccessed on May 10, 2010
- RettieAETaiGThe pharmocogenomics of warfarin: Closing in on personalized medicineMol Interv2006622322716960144
- JonasDEMcLeodHLGenetic and clinical factors relating to warfarin dosingTrends Pharmacol Sci20093037538619540002
- ThiLShawDBirdJWarfarin potentiation: A review of the “FAB-4” significant drug interactionsConsult Pharm20092422723019555137
- KrollDJShawHSOberliesNHMilk thistle nomenclature: Why it matters in cancer research and pharmacokinetic studiesIntegr Cancer Ther2007611011917548790